「vascular endothelial growth factor」に関連した動画の一覧

	VEGF  VEGF (Vascular Endothelial Growth Factor) is a signaling molecule that binds to receptors on blood vessels. The binding VEGF to the receptors signals the blood vessels to sprout and elongate toward the source of the VEGF. Tumors release VEGF, stimulating the development of their own blood supply thus supporting their further growth. This animation includes audio narration: please make sure your computer's volume is up so that you can hear it. Source : www.hhmi.org 2010年04月27日再生回数 553
	Vascular Endothelial Growth Factor  Dr. Joe talks about a key molecule in the vascular system. www.cell.com download.cell.com 2011年08月15日再生回数 621
	Growth Factor: Vascular Endothelial Growth Factor (VEGF)  Hemangioblast differentiated into RBCs or Endothelial Cells 2009年03月02日再生回数 624
	VEGF pathway: Target several targeted therapies against cancer Avastin Sutent Nexavar  Mechanism of action of VEGF (vascular endothelial growth factor) signalling pathway. Mécanisme d'action de la voie de signalisation du VEGF (facteur de croissance endothéliale vasculaire). EFP Website: www.efp-online.org. European Fellowship for Pharmacists 2010年07月14日再生回数 7776
	VEGF and EGFR pathways in detail: Target for new therapies against cancer  Mechanism of action of VEGF (vascular endothelial growth factor) and EGFR (epidermal growth factor receptor) signalling pathways. Mécanisme d'action des voies de signalisation du VEGF et de l'EGFR. EFP Website: www.efp-online.org. European Fellowship for Pharmacists 2010年07月14日再生回数 27795
	Angiogenic receptors - VEGF, Rate My Science  ratemyscience.com Publish and rate science matrix metalloproteinases (MMPs) are the invisible modelers of the blood vessel formation. Angiogenesis, the formation of new blood vessels from pre-existing ones, is a key event in tumour progression controlled by a balance between positive and negative regulators. Positive regulators include at least vascular endothelial growth factor family (VEGF-A, -B, -C, -D), fibroblast growth factors (FGF), placental-like growth factor (PlGF), angiopoietins, their tyrosine kinase receptors (VEGF-R1, -R2; Tie1 and Tie2) and neuropilin-1 (NRP-1), a co-receptor for VEGF. 2008年11月01日再生回数 9523
	VEGF and CNV  Vascular Endothelial Growth Factor (VEGF) and Chroidal Neovascularization (CNV). 2007年07月24日再生回数 1577
	Progression of wet Age-Related Macular Degeneration  Welcome to the AMD Resource Center, presented by the Angiogenesis Foundation. This animation will explain how wet AMD causes vision loss. Age-Related Macular Degeneration (AMD) is a disease that causes progressive damage to the macula, a central region of the retina. The retina is the light receiving nerve layer located in the back of the eye. The macula contains the densest population of nerve cells, called photoreceptors, and is particularly important for seeing detail and maintaining the central part of our vision. Central vision is important for ordinary daily activities like reading, driving, dialing the telephone, and recognizing faces. The macula is composed of several layers of specialized cells. The photoreceptors sit atop a layer of cells called retinal epithelial cells (RPE). Underneath these layers is a thin lining called Bruch's membrane. Beneath Bruch's membrane is the choroid, a network of blood vessels that provide oxygen and nutrients to the macula. As the eye ages, debris from the RPE cell layer, and surrounding tissues accumulates above and within the Bruch's membrane. The debris form deposits called drusen. The presence of drusen is usually the first sign of early dry AMD. As drusen accumulate, they can cause inflammation. Inflammatory cells are then recruited to the retina, and these cells, along with the RPE, begin releasing growth factors that cause blood vessels to grow. The primary growth factor released is called vascular endothelial growth ... 2012年04月24日再生回数 398
	Hereditary Haemorrhagic Telangiectasia Avastin Inj  Hereditary hemorrhagic telangiectasia (HHT) epistaxis is a difficult and messy problem for patients. The bleeding is unpredictable. Physicians have little to offer. Surgical outcomes are generally poor. A medical therapy such as a vascular endothelial growth factor (VEGF) inhibitor injection/ spray would be welcome by both patient and doctor. 2011年02月05日再生回数 994
	Dr. McDonald Explains Approved Angiogenesis Inhibitors  Donald M. McDonald, MD, PhD, a professor in the Department of Anatomy and an investigator in the Cardiovascular Research Institute at the University of California, San Francisco Comprehensive Cancer Center, discusses the three approved drugs that inhibit angiogenesis in cancer. The first drug he mentions is bevacizumab (Avastin), which is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). This drug is described as a larger molecule agent and is administered intravenously. McDonald mentions there are two small molecule drugs, oral agents, which are also available. The first of the antiangiogenesis agents is sunitinib (Sutent) which is a multi-targeted agent that blocks both VEGF and platelet-derived growth factor (PDGF) receptors. The second small-molecule drug is sorafenib (Nexavar) that also blocks the VEGF and PDGF receptors. The two small molecule drugs have a higher rate of adverse events because they inhibit multiple pathways. 2011年09月17日再生回数 209